カテゴリ： GlobalData, アメリカ, 企業調査

Vertex Pharmaceuticals Inc (VRTX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014219
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：82
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of novel drugs for the treatment of serious and life-threatening diseases. The company offers Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Its research and development efforts focus on influenza and bacterial infections, inflammatory diseases, cancer, neurological diseases and disorders including pain and cystic fibrosis. The company has several pipeline products for the treatment of cystic fibrosis, cancer, pain and influenza. It has operations in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc (VRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Partnerships 16
X-Chem Enters into Agreement with Vertex Pharma 16
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 17
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 18
Vertex Pharma Extends Co-Development Agreement With Cystic Fibrosis Foundation 19
Licensing Agreements 21
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Asset Transactions 27
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc – Key Competitors 30
Vertex Pharmaceuticals Inc – Key Employees 31
Vertex Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 35
Financial Announcements 35
Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 35
Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 38
Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 41
Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 44
Oct 25, 2016: Vertex Reports Third Quarter 2016 Financial Results 46
Jul 27, 2016: Vertex Reports Second Quarter 2016 Financial Results 48
Apr 27, 2016: Vertex Reports First Quarter 2016 Financial Results 50
Jan 27, 2016: Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results 54
Corporate Communications 57
Oct 17, 2017: Vertex Announces 10-Year, $500 Million Corporate Giving Commitment 57
Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 58
Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 59
Dec 02, 2016: Vertex Pharmaceuticals Announces Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 60
Government and Public Interest 61
Nov 01, 2017: Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 61
May 04, 2017: Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 62
Feb 24, 2016: Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 63
Product Approvals 64
Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 64
Clinical Trials 65
Nov 03, 2017: Vertex Announces Presentation of Data from Triple Combination (VX-440, VX-152 and VX-659) Regimen Studies at North American Cystic Fibrosis Conference 65
Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 66
Dec 21, 2016: Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis 67
Oct 27, 2016: Concert Pharmaceuticals Presents Poster at 2016 North American Cystic Fibrosis Conference 68
Oct 25, 2016: Vertex Announces Planned Initiation of Phase 2 Study Evaluating the Next-Generation Corrector VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis 69
Oct 25, 2016: Vertex Announces Planned Initiation of Phase 2 Study Evaluating the Next-Generation Corrector VX-440 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis 70
Oct 25, 2016: Vertex to Begin Clinical Development of Third Next-Generation Corrector VX-659 71
Jun 10, 2016: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference 72
Apr 28, 2016: Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis 73
Feb 29, 2016: Concert Pharmaceuticals Announces CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile to Kalydeco 74
Other Significant Developments 75
Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 75
Jan 10, 2016: Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases 78
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
X-Chem Enters into Agreement with Vertex Pharma 16
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 17
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 18
Vertex Pharma Extends Co-Development Agreement With Cystic Fibrosis Foundation 19
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc, Key Competitors 30
Vertex Pharmaceuticals Inc, Key Employees 31
Vertex Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[Vertex Pharmaceuticals Inc (VRTX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Danske Bank A/S：企業のM&A・事業提携・投資動向
    Danske Bank A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Danske Bank A/S Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Mitsui Fudosan Co., Ltd.：戦略・SWOT・企業財務分析
    Mitsui Fudosan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Fudosan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Centrais Eletricas de Santa Catarina S.A. (CLSC4)：企業の財務・戦略的SWOT分析
    Centrais Eletricas de Santa Catarina S.A. (CLSC4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • AC Immune SA (ACIU)：企業の財務・戦略的SWOT分析
    AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Halt Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Halt Medical Inc (Halt Medical) is a healthcare service center that develops, manufactures and commercializes medical treatment for women with symptomatic uterine fibroids. The center offers Acessa System, a minimally invasive laparoscopic outpatient procedure to treat uterine fibroids. It o …
  • Lundin Petroleum AB (LUPE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Lundin Petroleum AB (Lundin Petroleum) is an independent oil and gas exploration and production company that acquires, explores, develops and produces oil and gas properties in Norway. The company identifies and matures exploration targets, drill exploration wells, appraise discoveries, and …
  • Checkpoint Surgical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Checkpoint Surgical Inc (Checkpoint Surgical) is a medical device company that offers neuro-protective surgical devices. The company’s products include checkpoint stimulators and locators; and checkpoint head and neck systems. Its checkpoint stimulators and locators provide biphasic stimulat …
  • Daqo New Energy Corp (DQ)：電力：M&Aディール及び事業提携情報
    Summary Daqo New Energy Corp (Daqo Cayman) is a manufacturer of polysilicon and solar wafers. Through tolling agreements, the company also offers wafer original equipment manufacturer (OEM) services to external customers. It sells its products to solar cell and solar module manufacturers. Daqo Cayma …
  • Nobelpharma Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary NobelPharma Co Ltd (NobelPharma) is a pharmaceutical company which develops medicines for rare diseases and unmet medical needs. The Company’s pipeline products include NPC-07, NPC-09, NPC-12, NPC-14, NPC-15, NPC-16, NPC-17 and NPC-18. It offers its products in the therapeutic areas of oncol …
  • V. F. Corporation：企業の戦略・SWOT・財務情報
    V. F. Corporation - Strategy, SWOT and Corporate Finance Report Summary V. F. Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ContextVision AB (COV)：企業の財務・戦略的SWOT分析
    Summary ContextVision AB (ContextVision) is a medical technology company that specializes in image analysis and artificial intelligence software solutions. The company develops image enhancement software solutions for magnetic resonance imaging, digital pathology, ultrasound, X-ray, fluoroscopy, mam …
  • Brooks MacDonald Group PLC (BRK)：企業の財務・戦略的SWOT分析
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • CME Group Inc：企業の戦略・SWOT・財務情報
    CME Group Inc - Strategy, SWOT and Corporate Finance Report Summary CME Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • PhotoMedex Inc (PHMD)-製薬・医療分野：企業M&A・提携分析
    Summary PhotoMedex Inc (PhotoMedex) is a medical device company that provides dermatological solutions. The company offers Neova, Tricomin and IAMIN products. Its products are used in the treatment of skin diseases and conditions such as psoriasis, vitiligo, acne, actinic keratosis. PhotoMedex provi …
  • Calgary Scientific Inc-医療機器分野：企業M&A・提携分析
    Summary Calgary Scientific Inc (Calgary Scientific) is a scientific software company that provides technology solutions for the medical industry. The company offers ResolutionMD, a diagnostic medical imaging software solution that acts as an enterprise image viewer for doctors to view patient images …
  • Keppel Corporation Limited：企業の戦略・SWOT・財務情報
    Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Biosensors International Group Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Biosensors International Group Ltd (Biosensors) is a medical devices company. It develops, manufactures and markets medical devices. The company products find application in Interventional cardiology and critical care procedures. The company classifies its products into four categories: Inte …
  • Mediware Information Systems Inc-医療機器分野：企業M&A・提携分析
    Summary Mediware Information Systems Inc (Mediware) is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solutions are equipped in blood banks …
  • HOCHTIEF AG：戦略・SWOT・企業財務分析
    HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report Summary HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Tyson Foods Inc：企業のM&A・事業提携・投資動向
    Tyson Foods Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tyson Foods Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆